Format

Send to

Choose Destination
Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.

Author information

1
Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: gertz.morie@mayo.edu.
2
Division of Hematolgy, Mayo Clinic, Rochester, MN.
3
Department of Medicine, Hematology/Oncology Division, Mayo Clinic, Rochester, MN.
4
Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.

Abstract

Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program to reduce day-100 all-cause mortality. Currently our mortality has been reduced to 0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater. Outpatient transplantation is safe and reduces patient-incurred costs.

PMID:
29304921
DOI:
10.1016/j.mayocp.2017.09.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center